卵泡刺激素受体及其靶向药物的研究进展 - tumor - 肿瘤.pdf

肿瘤2014 年9 月第34 卷第9 期　TUM OR Vol. 34, September 2014　　 863 DOI: 10.3781/j .issn.1000-7431.2014.09.014 Copyright© 2014 by TUM OR Review 综述 · 卵泡刺激素受体及其靶向药物的研究进展 1 2 1, 2 朱　晨 ，杨润琳 ，杨　敏 1. 南京医科大学第一附属医院放疗科，江苏南京　210029；2. 江苏省原子医学研究所分子影像中心，江苏无锡　214063 [摘要]　卵泡刺激素受体 （follicle stimulating hormone receptor ，FSHR ）是一种G 蛋白偶联受体，仅在哺乳动物 生殖系统中痕量表达。新近研究发现，FSHR 在多种肿瘤 （如前列腺癌、乳腺癌、肝癌和肾癌等）的血管内皮上 高度表达，并在疾病的发展进程中发挥重要作用。因此，FSHR 是肿瘤诊治的一个潜在的靶点。开发FSHR 靶向 药物将有利于肿瘤的诊断、靶向治疗及个体化方案的选择和预后的判定。本文就FSHR 及其特异性配体的研究进 展作一综述。 [关键词]　肿瘤；卵泡刺激素；放射性核素显像；分子探针技术 [中图分类号]　R730.4 [文献标志码] A [文章编号]　1000-7431 (2014) 09-0863-05 Advances in follicle stimulating hormone receptor and its targeted drugs 1 2 1, 2 ZHU Chen , YANG Run-lin , YANG Min 1. Department of Radiation Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China; 2. Molecular Imaging Center, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, Jiangsu Province, China [A BSTRACT]　Follicle stimulating hormone receptor (FSHR) belongs to the G protein-coupled receptor family and is only low-expressed in reproductive organs of mammals. Recent studies have shown that FSHR is overexpressed in vascular endothelium of multiple types of human tumors including prostate cancer, breast cancer, liver cancer and kidney cancer, etc, and it plays an important role in the progression of cancer. Thus, FSHR is a potential target for diagnosis and treatment of tumors. Development of drugs targeting FSHR is beneficial to diagnosis, targeted therapy, selection of individualized drug therapy and prognosis of tumors. This paper summarizes the advances in FSHR and its specific ligands. [KEY W ORDS]　Neoplas